Case Summary:

Our EB1-A (Alien of Extraordinary Ability) client from India was one of the few leading head, neck, and esophageal cancer experts in cancer biology. He had achieved a consistent and notable record of success and influence in these areas of study before coming to us. He is especially well-known for investigating the expression pattern of stem-cell-related markers and signaling intermediates in head and neck cancers.

While prepping his petition, we came across several pieces of evidence that were pertinent to proving him meritorious for his EB1-A case. Our team collected these pieces of evidence and put them together for his application. Some of them were as follows:

• The field has recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 120 times.
• He has actively engaged his peers in the field of cancer biology by authoring and co-authoring 11 peer-reviewed articles and 1 book chapter that have been published in international journals.
• He has made original contributions of major significance to the field of cancer biology, including but not limited to original studies on the expression pattern and oncogenesis of head and neck cancers, etc.
• Due to its great applicability in the field, his research in cancer biology has been cited 270 times in other peer-reviewed journal articles according to Google Scholar.
• In fact, he is one of the top 1% of most highly cited authors publishing on topics in cancer biology over the past 10 years according to Microsoft Academic, and his publications have been cited by researchers in at least 28 countries according to Google Scholar.
• His study has been supported by funding from the Department of Veterans Affairs and the National Cancer Institute, the National Cancer Institute, and the National Institutes of Health.
• He has obtained 4 letters recommending his research in the area. These letters come from experts in his field and in allied fields who have worked with him or know him remotely via his research. Two of them had the following to say of him:

“[The client] is conducting groundbreaking research on various forms of head and neck cancer, which comprise a substantial portion of the total diagnoses of the disease. For example, in the United States, nearly 4% of all cancer patients suffer from some form of head and neck cancer. It follows that [the client’s] research discovering salient protein biomarkers of cancer and novel molecular targets for cancer therapeutics constitutes a meaningful contribution to the health of the global population.”

“[The client] has helped improve patient outcomes by making the diagnosis and treatment process for head and neck cancers far more manageable and easier to perform. He achieved this breakthrough through his investigations into the use of biomarkers, signaling intermediates, and other cellular markers, especially dysregulated proteins, as tools to advance early cancer detection and the overall understanding of the oncogenesis of head and neck cancers. [Client’s] work is extremely useful for bettering cancer diagnoses, treatments, and, ultimately, outcomes in the U.S., cementing the importance of his uninterrupted research in the nation.”

All of these facts were incredibly helpful in showing that our client was indeed a meritorious researcher of extraordinary ability finally winning him the approval in just 6 days. We thank him for his trust and for allowing us to lead the way. We wish him the very best in all future endeavors.